These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34887227)

  • 21. Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review.
    Parra A; Hernández C; Prieto-Pinto L
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(9):1017-1026. PubMed ID: 37665685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
    Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
    J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
    Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
    Denys H; Martinez-Mena CL; Martens MT; D'Hondt RG; Graas ML; Evron E; Fried G; Ben-Baruch NE; Vulsteke C; Van Steenberghe MM
    Breast Cancer Res Treat; 2020 May; 181(1):97-105. PubMed ID: 32240454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.
    Yamshiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Ohno S; Kuroi K; Takano T; Takada M; Yasuno S; Morita S; Toi M
    Int J Clin Oncol; 2015 Aug; 20(4):709-22. PubMed ID: 25666483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous versus intravenous administration of Trastuzumab: a minimization cost analysis with real world data from a reference cancer centre in Peru.
    Otoya I; Valdiviezo N; Roque K; Morante Z; Vidaurre T; Neciosup SP; Calderón MJ; Gomez HL
    Ecancermedicalscience; 2024; 18():1708. PubMed ID: 39021543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
    O'Shaughnessy J; Sousa S; Cruz J; Fallowfield L; Auvinen P; Pulido C; Cvetanovic A; Wilks S; Ribeiro L; Burotto M; Klingbiel D; Messeri D; Alexandrou A; Trask P; Fredriksson J; Machackova Z; Stamatovic L;
    Eur J Cancer; 2021 Jul; 152():223-232. PubMed ID: 34147014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.
    North RT; Harvey VJ; Cox LC; Ryan SN
    Clinicoecon Outcomes Res; 2015; 7():423-30. PubMed ID: 26251623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden.
    Valachis A; Sundqvist M; Carlsson L; Li B; Chiesa F; Uhde M; Sanglier T
    Future Oncol; 2019 Aug; 15(23):2733-2741. PubMed ID: 31306041
    [No Abstract]   [Full Text] [Related]  

  • 30. Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab.
    Franken M; Kanters T; Coenen J; de Jong P; Jager A; Groot CU
    Breast; 2020 Aug; 52():71-77. PubMed ID: 32447129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
    Elsisi GH; Nada Y; Rashad N; Carapinha J; Noor AO; Almasri DM; Zaidy MA; Foad A; Khaled H
    J Med Econ; 2020 Jun; 23(6):575-580. PubMed ID: 32011199
    [No Abstract]   [Full Text] [Related]  

  • 32. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
    Pivot X; Gligorov J; Müller V; Barrett-Lee P; Verma S; Knoop A; Curigliano G; Semiglazov V; López-Vivanco G; Jenkins V; Scotto N; Osborne S; Fallowfield L;
    Lancet Oncol; 2013 Sep; 14(10):962-70. PubMed ID: 23965225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of Trastuzumab-HER2 Engagement In Vitro and In Vivo.
    Rudkouskaya A; Smith JT; Intes X; Barroso M
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33348564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
    Ciruelos EM; Montaño A; Rodríguez CA; González-Flores E; Lluch A; Garrigós L; Quiroga V; Antón A; Malón D; Chacón JI; Velasco M; Gonzalez-Cortijo L; Jolis L; Echarri MJ; Muñoz M; Pascual T; Amigo Y; Casas M; Carrasco E; Casas A
    Eur J Cancer Care (Engl); 2020 Jul; 29(4):e13253. PubMed ID: 32578279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients.
    González García J; Gutiérrez Nicolás F; Ramos Díaz R; Nazco Casariego GJ; Viña Romero MM; Llabres Martinez M; Llanos Muñoz M; Batista López JN; Jiménez Sosa A; Ceballos Lenza I; Cruz Jurado J
    Ann Pharmacother; 2020 Aug; 54(8):775-779. PubMed ID: 31971005
    [No Abstract]   [Full Text] [Related]  

  • 36. Estimation of the cost of treatment by chemotherapy for early breast cancer in Morocco.
    Boutayeb S; Boutayeb A; Ahbeddou N; Boutayeb W; Ismail E; Tazi M; Errihani H
    Cost Eff Resour Alloc; 2010 Sep; 8():16. PubMed ID: 20828417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting.
    Barat EC; Arrii MLE; Soubieux-Bourbon A; Daouphars M; Varin R; Tilleul PR
    Breast; 2023 Dec; 72():103588. PubMed ID: 37857129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach.
    DuMond B; Patel V; Gross A; Fung A; Weber S
    J Oncol Pharm Pract; 2021 Jul; 27(5):1214-1221. PubMed ID: 33719721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
    Zambetti M; Montemurro F; Morandi P; Zamagni C; Brandes AA; Bisagni G; Cagossi K; Bengala C; Gori S; Iannacone C; Stell A; Gianni L
    Eur J Cancer; 2018 Dec; 105():61-70. PubMed ID: 30396014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients.
    Farolfi A; Silimbani P; Gallegati D; Petracci E; Schirone A; Altini M; Masini C
    Oncotarget; 2017 Oct; 8(46):81343-81349. PubMed ID: 29113393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.